摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-苄基-1H-吡咯-3-甲醛 | 30186-48-2

中文名称
1-苄基-1H-吡咯-3-甲醛
中文别名
——
英文名称
1-benzyl-1H-pyrrole-3-carbaldehyde
英文别名
1-benzylpyrrole-3-carbaldehyde
1-苄基-1H-吡咯-3-甲醛化学式
CAS
30186-48-2
化学式
C12H11NO
mdl
——
分子量
185.225
InChiKey
VVUVCKSHUSFLOE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    22
  • 氢给体数:
    0
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2933990090

SDS

SDS:bcd4db3c7c5bc4da4a084013bb1edcfa
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-苄基-1H-吡咯-3-甲醛 在 sodium tetrahydroborate 、 氯化铵 作用下, 以 甲醇 为溶剂, 反应 2.0h, 以80%的产率得到(1-benzyl-1H-pyrrol-3-yl)methanol
    参考文献:
    名称:
    溴氧化反应制得的3-糠基胺中的3-甲酰基吡咯
    摘要:
    在丙酮-水溶液中用溴氧化3-糠胺3a-e得到高收率的N-取代的3-甲酰基吡咯4a-e。提出了通过Clauson-Kaas反应的反应机理,然后通过2-烯-1,4-二酮13和14的顺反异构化来解释吡咯4a-e的形成。
    DOI:
    10.1002/jccs.201000195
  • 作为产物:
    描述:
    3-呋喃甲醇三溴化磷 作用下, 以 四氢呋喃丙酮 为溶剂, 反应 23.0h, 生成 1-苄基-1H-吡咯-3-甲醛
    参考文献:
    名称:
    溴氧化反应制得的3-糠基胺中的3-甲酰基吡咯
    摘要:
    在丙酮-水溶液中用溴氧化3-糠胺3a-e得到高收率的N-取代的3-甲酰基吡咯4a-e。提出了通过Clauson-Kaas反应的反应机理,然后通过2-烯-1,4-二酮13和14的顺反异构化来解释吡咯4a-e的形成。
    DOI:
    10.1002/jccs.201000195
点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION<br/>[FR] COMPOSÉS DE BENZYLAMINE SUBSTITUÉS, LEUR UTILISATION EN MÉDECINE, EN PARTICULIER DANS LE TRAITEMENT D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE C (VHC)
    申请人:ASTEX THERAPEUTICS LTD
    公开号:WO2013064538A1
    公开(公告)日:2013-05-10
    The invention provides compounds of the formula (I): or a salt, N-oxide or tautomer thereof, wherein A is CH, CF or nitrogen; E is CH, CF or nitrogen; and R0 is hydrogen or C1-2 alkyl; R1a is selected from CONH2; CO2H; an optionally substituted acyclic C1-8 hydrocarbon group; and an optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S; R2 is selected from hydrogen and a group R2a; R2a is selected from an optionally substituted acyclic d-8 hydrocarbon group; an optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1 or 2 ring members are heteroatom ring members selected from O, N and S; and an optionally substituted bicyclic heterocyclic group of 9 or 10 ring members, of which 1 or 2 ring members are nitrogen atoms; wherein at least one of R1 and R2 is other than hydrogen; R3 is an optionally substituted 3- to 10-membered monocyclic or bicyclic carbocyclic or heterocyclic ring containing 0, 1, 2 or 3 heteroatom ring members selected from N, O and S; R4a is selected from halogen; cyano; C1-4 alkyl optionally substituted with one or more fluorine atoms; C1-4 alkoxy optionally substituted with one or more fluorine atoms; hydroxy-C1-4 alkyl; and C1-2 alkoxy-C1-4 alkyl; R5 is selected from hydrogen and a substituent R5a; and R5a is selected from C1-2 alkyl optionally substituted with one or more fluorine atoms; C1-3 alkoxy optionally substituted with one or more fluorine atoms; halogen; cyclopropyl; cyano; and amino, The compounds have activity against hepatitis C virus and can be used in the prevention or treatment of hepatitis C viral infections.
    该发明提供了以下式(I)的化合物,或其盐、N-氧化物或互变异构体,其中A为CH、CF或氮;E为CH、CF或氮;R0为氢或C1-2烷基;R1a选自CONH2;CO2H;一个可选择取代的非环状C1-8碳氢化合物基团;以及一个可选择取代的含有3至7个环成员的单环碳环或杂环基团,其中0、1、2、3或4个是从O、N和S中选择的杂原子环成员;R2选自氢和一个基团R2a;R2a选自一个可选择取代的非环状d-8碳氢化合物基团;一个可选择取代的含有3至7个环成员的单环碳环或杂环基团,其中0、1或2个环成员是从O、N和S中选择的杂原子环成员;以及一个可选择取代的含有9或10个环成员的双环杂环基团,其中1或2个环成员是氮原子;其中R1和R2中至少一个不是氢;R3选自一个可选择取代的含有0、1、2或3个从N、O和S中选择的杂原子环成员的3至10个成员的单环或双环碳环或杂环环;R4a选自卤素;氰基;C1-4烷基,可选择取代一个或多个氟原子;C1-4烷氧基,可选择取代一个或多个氟原子;羟基-C1-4烷基;和C1-2烷氧基-C1-4烷基;R5选自氢和一个取代基R5a;R5a选自C1-2烷基,可选择取代一个或多个氟原子;C1-3烷氧基,可选择取代一个或多个氟原子;卤素;环丙基;氰基;和氨基。这些化合物对丙型肝炎病毒具有活性,并可用于预防或治疗丙型肝炎病毒感染。
  • Modulating Reactivity and Diverting Selectivity in Palladium-Catalyzed Heteroaromatic Direct Arylation Through the Use of a Chloride Activating/Blocking Group
    作者:Benoît Liégault、Ivan Petrov、Serge I. Gorelsky、Keith Fagnou
    DOI:10.1021/jo902515z
    日期:2010.2.19
    Through the introduction of an aryl chloride substituent, the selectivity of palladium-catalyzed direct arylation may be diverted to provide alternative regioisomeric products in high yields. In cases where low reactivity is typically observed, the presence of the carbon−chlorine bond can serve to enhance reactivity and provide superior outcomes. From a strategic perspective, the C−Cl bond is easily
    通过引入芳基氯取代基,可以改变钯催化的直接芳基化的选择性,从而以高收率提供替代的区域异构产物。在通常观察到低反应性的情况下,碳-氯键的存在可以起到增强反应性和提供优异结果的作用。从战略角度看,C-Cl键易于引入,可用于各种后续转化中,从而以最少的底物预活化提供大量高度官能化的杂环。还已经从力学上评估了C-Cl官能团对直接芳基化反应性的影响,并且观察到的反应性特征与协同的金属化-去质子化途径所预测的非常相关。
  • FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF
    申请人:Sakai Nozomu
    公开号:US20090137595A1
    公开(公告)日:2009-05-28
    The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the specification, except a particular compound, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor or a cancer metastasis suppressor.
    本发明提供了一种具有强大激酶抑制活性的融合杂环衍生物及其用途。 一种由以下式(I)表示的化合物: 其中除了特定化合物或其盐外,每个符号如规范中定义,以及含有该化合物或其前药的药用剂,该化合物是激酶(VEGFR、VEGFR2、PDGFR、Raf)抑制剂,血管生成抑制剂,用于癌症的预防或治疗的药剂,癌症生长抑制剂或癌症转移抑制剂。
  • PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME
    申请人:Tanaka Keigo
    公开号:US20090082403A1
    公开(公告)日:2009-03-26
    Anti-fungal agent having excellent anti-fungal action physicochemical properties including safety and water solubility. Compound represented by formula (I), or salt thereof: wherein R 1 represents hydrogen, halogen, amino, R 11 —NH— wherein R 11 represents C 1-6 alkyl, hydroxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkyl, or C 1-6 alkoxycarbonyl C 1-6 alkyl, R 12 —(CO)—NH— wherein R 12 represents C 1-6 alkyl group or C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkyl, hydroxy C 1-6 alkyl, cyano C 1-6 alkyl, C 1-6 alkoxy, or C 1-6 alkoxy C 1-6 alkyl or a phosphonoamino group; R 2 represents hydrogen, C 1-6 alkyl, amino, or a di C 1-6 alkylamino group or a phosphonoamino group; one of X and Y is nitrogen while the other is nitrogen or oxygen; ring A represents a 5- or 6-member heteroaryl ring or a benzene ring which may have a halogen atom or 1 or 2 C 1-6 alkyl groups; Z represents a single bond, a methylene group, an ethylene group, oxygen, sulfur, —CH 2 O—, —OCH 2 —, —NH—, —CH 2 NH—, —NHCH 2 —, —CH 2 S—, or —SCH 2 —; R 3 represents hydrogen or halogen or C 1-6 alkyl, C 3-8 cycloalkyl, C 6-10 aryl, a 5- or 6-member heteroaryl group or a 5- or 6-member nonaromatic heterocyclic group which may have 1 or 2 substituents; and R 4 represents hydrogen or halogen; provided that either R 1 or R 2 represents a phosphonoamino group.
    抗真菌剂具有优异的抗真菌作用物理化学性质,包括安全性和水溶性。化合物由式(I)表示,或其盐: 其中R1代表氢,卤素,氨基,R11—NH—其中R11代表C1-6烷基,羟基C1-6烷基,C1-6烷氧基C1-6烷基,或C1-6烷氧羰基C1-6烷基,R12—(CO)—NH—其中R12代表C1-6烷基或C1-6烷氧基C1-6烷基,C1-6烷基,羟基C1-6烷基,氰基C1-6烷基,C1-6烷氧基,或C1-6烷氧基C1-6烷基或磷酰氨基团;R2代表氢,C1-6烷基,氨基,或二C1-6烷基氨基团或磷酰氨基团;X和Y中的一个是氮,另一个是氮或氧;环A代表5-或6-成员杂芳基环或可能具有卤素原子或1或2个C1-6烷基基团的苯环;Z代表单键,亚甲基基团,乙烯基团,氧,硫,—CH2O—,—OCH2—,—NH—,—CH2NH—,—NHCH2—,—CH2S—,或—SCH2—;R3代表氢或卤素或C1-6烷基,C3-8环烷基,C6-10芳基,5-或6-成员杂芳基团或可能具有1或2个取代基的5-或6-成员非芳香杂环基;和R4代表氢或卤素;前提是R1或R2中的一个代表磷酰氨基团。
  • Heterocycles substituted pyridine derivatives and antifungal agent containing thereof
    申请人:Tanaka Keigo
    公开号:US20070105904A1
    公开(公告)日:2007-05-10
    An object of the present invention is to provide an antifungal agent which has excellent antifungal effects and is superior in terms of its physical properties, safety and metabolic stability. According to the present invention, there is disclosed a compound represented by the following formula (I), or a salt thereof: wherein R 1 represents a hydrogen atom, a halogen atom, an amino group, a C 1-6 alkyl group, a C 1-6 alkoxy group or a C 1-6 alkoxy C 1-6 alkyl group; R 2 represents a hydrogen atom, a C 1-6 alkyl group, an amino group or a di C 1-6 alkylamino group; one of X and Y is a nitrogen atom while the other is a nitrogen atom or an oxygen atom; ring A represents a 5- or 6-member heteroaryl ring or a benzene ring which may have a halogen atom, or 1 or 2 C 1-6 alkyl groups; Z represents a single bond, a methylene group, an ethylene group, an oxygen atom, a sulfur atom, —CH 2 O—, —OCH 2 —, —NH—, —CH 2 NH—, —NHCH 2 —, —CH 2 S—, or —SCH 2 —; R 3 represents a hydrogen atom, a halogen atom, a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 6-10 aryl group, a 5- or 6-member heteroaryl group, or 5- or 6-member non-aromatic heterocyclic group which may have 1 or 2 substituents; and R 4 represents a hydrogen atom or a halogen atom.
    本发明的一个目的是提供一种具有优异的抗真菌效果并在其物理性质、安全性和代谢稳定性方面优越的抗真菌剂。根据本发明,公开了以下式(I)所代表的化合物或其盐: 其中R1代表氢原子、卤素原子、氨基、C1-6烷基、C1-6烷氧基或C1-6烷氧基C1-6烷基;R2代表氢原子、C1-6烷基、氨基或二C1-6烷基氨基中的一个;X和Y中的一个是氮原子,另一个是氮原子或氧原子;环A代表一个5-或6-成员杂芳基环或可能具有卤素原子、1个或2个C1-6烷基的苯环;Z代表一个单键、一个亚甲基基、一个乙烯基、一个氧原子、一个硫原子、-CH2O-、-OCH2-、-NH-、-CH2NH-、-NHCH2-、-CH2S-或-SCH2-;R3代表氢原子、卤素原子、C1-6烷基、C3-8环烷基、C6-10芳基、一个5-或6-成员杂芳基、或可能具有1个或2个取代基的5-或6-成员非芳香杂环基;R4代表氢原子或卤素原子。
查看更多